Wrong cost-effectiveness analysis

[Francisco Javier Díez]

In this network, we assume that we know, before applying the therapy, whether the disease is present or not. Therefore, it is not worth doing the test. However, OM recommends doing the test when the willingness to pay is above 8.44e16. It seems to be due to the loss of precision when doing calculations with very large numbers.